Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust. As part of the pilot, patients visiting Rapid Access Chest Pain Clinics (RACPCs) who undergo a CCTA scan as per NICE guidance, will have their scan analysed by the CaRi-Heart platform in order to help healthcare professionals better assess patients’ cardiac risk to optimise medical management.

The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans. CaRi-Heart’s newest product component, the CaRi-PlaqueTM module, is a web-based software medical device designed for trained operators to analyse cardiac computed tomography angiography (CCTA) data for characterisation and quantification of coronary plaque components. Trained operators can use the CaRi-Plaque module to generate a report describing the physical characteristics of coronary plaque powered by artificial intelligence (AI) algorithms.

The CaRi-Heart report quantifies coronary inflammation via the patient-specific Fat Attenuation Index ScoreTM (FAI ScoreTM), which is a novel and patented biomarker for the measurement of coronary inflammation, measured for each coronary artery. The CaRi-Heart report also provides the CaRi-Heart Risk, which assesses the overall 8-year risk of a fatal heart attack (based on coronary inflammation status, plaque, and clinical risks factors). Research studies have shown that abnormal FAI is associated with a 6-9 times higher risk for fatal heart attacks and 5 times higher risk for non-fatal heart attacks1.

“Inflammation plays an important part in the development of atherosclerosis and is a strong predictor of cardiovascular disease progression and events”, said Professor Keith Channon, Caristo Diagnostics Chief Medical Officer, “Previously, chest pain clinics have returned most patients back to primary care without a defined prevention or treatment pathway. With coronary inflammation and plaque evaluation provided by the CaRi-Heart analysis, the clinical team will be able to use the additional information to identify at-risk patients more effectively and optimize their treatment, so future cardiac events can be prevented.”

“Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England”, said Frank Cheng, Caristo Diagnostics CEO, “We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world”.

 

Source:caristo.com

Report Abuse